Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure S1a.
Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure S1B.
Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure S2a.
Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure S2b
Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure S3.
Supplemental Figures for:
Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial
Wei Guo et al.

Figure S4.